Moers A P H A, Hallett R L, Burrow R, Schallig H D F H, Sutherland C J, van Amerongen A
Biomolecular Sensing & Diagnostics, Food & Biobased Research, Wageningen University and Research Centre, Wageningen, The Netherlands.
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Antimicrob Agents Chemother. 2015 Jan;59(1):365-71. doi: 10.1128/AAC.03395-14. Epub 2014 Nov 3.
The resistance of Plasmodium falciparum to some antimalarial drugs is linked to single-nucleotide polymorphisms (SNPs). Currently, there are no methods for the identification of resistant parasites that are sufficiently simple, cheap, and fast enough to be performed at point-of-care, i.e., in local hospitals where drugs are prescribed. Primer extension methods (PEXT) were developed to identify 4 SNPs in P. falciparum positioned at amino acids 86, 184, and 1246 of the P. falciparum multidrug resistance 1 gene (pfmdr1) and amino acid 76 of the chloroquine resistance transporter gene (pfcrt). The PEXT products were visualized by a nucleic acid lateral flow immunoassay (NALFIA) with carbon nanoparticles as the detection labels. PCR-PEXT-NALFIAs showed good correlation to the reference methods, quantitative PCR (qPCR) or direct amplicon sequence analysis, in an initial open-label evaluation with 17 field samples. The tests were further evaluated in a blind study design in a set of 150 patient isolates. High specificities of 98 to 100% were found for all 4 PCR-PEXT genotyping assays. The sensitivities ranged from 75% to 100% when all PEXT-positive tests were considered. A number of samples with a low parasite density were successfully characterized by the reference methods but failed to generate a result in the PCR-PEXT-NALFIA, particularly those samples with microscopy-negative subpatent infections. This proof-of principle study validates the use of PCR-PEXT-NALFIA for the detection of resistance-associated mutations in P. falciparum, particularly for microscopy-positive infections. Although it requires a standard thermal cycler, the procedure is cheap and rapid and thus a potentially valuable tool for point-of-care detection in developing countries.
恶性疟原虫对某些抗疟药物的耐药性与单核苷酸多态性(SNP)有关。目前,尚无足够简单、廉价且快速到能够在医疗现场(即在开药的当地医院)进行操作的耐药寄生虫鉴定方法。引物延伸法(PEXT)被开发用于鉴定恶性疟原虫中位于恶性疟原虫多药耐药1基因(pfmdr1)的第86、184和1246位氨基酸以及氯喹抗性转运蛋白基因(pfcrt)的第76位氨基酸处的4个SNP。PEXT产物通过以碳纳米颗粒作为检测标记的核酸侧向流动免疫分析(NALFIA)进行可视化。在对17份现场样本的初始开放标签评估中,PCR-PEXT-NALFIA与参考方法定量PCR(qPCR)或直接扩增子序列分析显示出良好的相关性。这些检测在一组150份患者分离株的盲法研究设计中得到进一步评估。所有4种PCR-PEXT基因分型检测的特异性均高达98%至100%。当考虑所有PEXT阳性检测时,灵敏度范围为75%至100%。一些寄生虫密度低的样本通过参考方法成功鉴定,但在PCR-PEXT-NALFIA中未能得出结果,尤其是那些镜检阴性的亚临床感染样本。这项原理验证研究证实了PCR-PEXT-NALFIA可用于检测恶性疟原虫中与耐药性相关的突变,特别是对于镜检阳性感染。尽管它需要一台标准的热循环仪,但该方法廉价且快速,因此对于发展中国家的医疗现场检测可能是一种有价值的工具。